APA (7th ed.) Citation

Cortes, J. E., Roboz, G. J., Baer, M. R., Jonas, B. A., Schiller, G. J., Yee, K., . . . Group, t. O. C. T. S. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. BMC.

Chicago Style (17th ed.) Citation

Cortes, Jorge E., et al. Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-label Phase 1/2 Trial. BMC.

MLA (9th ed.) Citation

Cortes, Jorge E., et al. Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-label Phase 1/2 Trial. BMC.